

May 27, 2021

For Immediate Release

H.U. Group Holdings, Inc.
MICIN, Inc.

H.U. Group and MICIN Commence Verification of Online Outpatient Clinic for Patients with Fever

～ Aiming to Prevent the Spread of the COVID-19～

H.U. Group Holdings, Inc. (President and Group CEO: Shigekazu Takeuchi; Head Office: Shinjuku-ku, Tokyo) and MICIN, Inc. (CEO: Seigo Hara; Head Office: Chiyoda-ku, Tokyo; hereinafter "MICIN") will commence the verification of an online outpatient fever clinic business, which will allow patients with fever or other symptoms to receive online medical consultations and take both COVID-19 and influenza tests at home, without going to a medical institution. The subject of this verification will be H.U. Group employees and their families.

According to the current guidelines from the Japanese Ministry of Health, Labour and Welfare, patients with fever or other symptoms should visit a designated medical institution and take a dedicated test if the doctor suspects they are infected by COVID-19. There is a possibility that patients may infect others or themselves become infected by others on their way to or at the medical institution where they will have the consultation. In this business verification, patients with fever or other symptoms will be connected to a partner medical institution online and conduct proper testing with rapid antigen test kits by themselves under the guidance of a medical doctor, which will enable a diagnosis of COVID-19 or influenza without going to a medical institution.

<Overview of Verification of Online Outpatient Clinic>

[Target group]

H.U. Group employees and their families (estimated number: around 3,000)

[Rapid antigen test kits to be used]

Rapid antigen test kits manufactured by Fujirebio, Inc. (a consolidated subsidiary of H.U. Group Holdings Inc.)

- ESPLINE® SARS-CoV-2

(Authorization number under the Pharmaceutical Affairs Law: 30200EZX00026000, pharmaceutical product for in vitro diagnostic use)

- ESPLINE® Influenza A&B-N

(Authorization number under the Pharmaceutical Affairs Law: 21500AMZ00511000, pharmaceutical product for in vitro diagnostic use)

[Verification period]

From June 2021 onward (scheduled to take about three months)

[Business verification steps]

- ① Those who participate in this business verification (hereinafter "the participants") receive the above-mentioned two rapid antigen test kits in advance (to be distributed at partner pharmacies*¹).
- ② The participants access WithWellness,*² the smartphone application for personal health records (PHR) when they have a fever or other symptoms.
- ③ The participants use “curon”, the MICIN's online medical consultation service platform which is linked to WithWellness, to seek medical attention from a doctor who belongs to a partner medical institution.
- ④ The participants conduct testing using the rapid antigen test kits by themselves, under a doctor/nurse's guidance.
- ⑤ The doctor confirms the test result over the screen and makes a diagnosis. If the result is COVID-19 positive, the doctor will give the necessary guidance and report to the public health center.

Through this business verification, the two companies plan to verify the effectiveness of this new online outpatient fever clinic system utilizing the rapid antigen test kits, and consider business/service development in consultation with partner organizations.

By addressing social issues in the medical field and promoting new business development, H.U. Group will continue to create new value in healthcare and thereby contribute to human health and the future of medical care.

*1. The kits will be distributed to the participants with the cooperation of Qol Co., Ltd. (President and Representative Director: Shinobu Karasawa; Head Office: Minato-ku, Tokyo).

*2. WithWellness is an application provided by Ishinban, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc.

To inquire about this announcement, please use the contact information below.

H.U. Group Holdings, Inc.

For members of the media:

Public Relations Section, Corporate Communications Dept.

Phone: +81-3-6279-0884

Email: pr@hugp.com

For investors and analysts:

IR/SR Section, Corporate Communications Dept.

Phone: +81-3-5909-3337

Email: ir@hugp.com

MICIN, Inc.

Personnel in charge of public relations: Shinohara Email: pr@micin.jp